Alpha-1 antitrypsin deficiency and the risk of hepatocellular carcinoma in end-stage liver disease

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 7, Issue 10

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Hepatology

ISSN

1948-5182

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Study

World J Hepatol. Jun 8, 2015; 7(10): 1427-1432
Published online Jun 8, 2015. doi: 10.4254/wjh.v7.i10.1427

Full Size Figure Download Figure

Figure 1 Cumulative incidence of hepatocellular carcinoma. HCC: Hepatocellular carcinoma; A1ATD: Alpha-1 antitrypsin deficiency.

Citation: Antoury C, Lopez R, Zein N, Stoller JK, Alkhouri N. Alpha-1 antitrypsin deficiency and the risk of hepatocellular carcinoma in end-stage liver disease. World J Hepatol 2015; 7(10): 1427-1432
URL: https://www.wjgnet.com/1948-5182/full/v7/i10/1427.htm
DOI: https://dx.doi.org/10.4254/wjh.v7.i10.1427

Antoury C, Lopez R, Zein N, Stoller JK, Alkhouri N. Alpha-1 antitrypsin deficiency and the risk of hepatocellular carcinoma in end-stage liver disease. World J Hepatol 2015; 7(10): 1427-1432 [PMID: 26052388 DOI: 10.4254/wjh.v7.i10.1427]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.